Carvedilol is a b-adrenoceptor antagonist used clinically to treat chronic heart failure as well as hypertension, angina pectoris, and cardiac arrhythmias.
In the previous study, we investigated the effect of genetic polymorphisms of cytochrome P450 (CYP) 2D6 on the pharmacokinetics of R-and S-carvedilol in 23 healthy Japanese volunteers.
8) The large interindividual variability was observed in the pharmacokinetics of carvedilol, and the coefficient of variation of the weight (WT)-corrected oral clearance ((CL/F)/ WT) value among the subjects was 36.1%. In addition, the (CL/F)/WT value was highly correlated with the apparent distribution volume ((V/F)/WT) value among the subjects, suggesting that the interindividual difference in bioavailability (F) was at least partly responsible for the pharmacokinetic variability of carvedilol. The (CL/F)/WT and (V/F)/WT values of R-and S-carvedilol were significantly lower in healthy volunteers with at least one CYP2D6*10 allele than those with the CYP2D6*1/*1 and *1/*2 genotype. The result suggested that the systemic and/or pre-systemic metabolism of R-and S-carvedilol in the liver is significantly decreased in Japanese subjects with the CYP2D6*10 allele.
Carvedilol is metabolized extensively via aliphatic sidechain oxidation and conjugation pathways, as well as the aromatic ring oxidation pathway which is mediated mainly by CYP2D6. 6) Oldham et al. reported that considerable metabolic activity for carvedilol is observed in CYP1A2, 2C9, 2D6, and 3A4. 9) On the other hand, it is still unclear whether the other P450s are involved in the metabolism of carvedilol. However, a substrate of CYP2C9, such as phenytoin, is partly catalyzed by another CYP2C subfamily, CYP2C19. 10) CYP3A5 is another important CYP3A protein in the liver, the substrate specificity of which largely overlaps with that of CYP3A4. 11) In addition, Ohno et al. reported that UDP-glucuronosyltransferase (UGT) 1A1, 2B4, and 2B7 as well as human hepatic microsomes are capable of catalyzing the glucuronidation of carvedilol. 12) Moreover, carvedilol has high affinity for the multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp). Giessmann et al. reported that the intestinal expression of P-gp is a major variable in the disposition of carvedilol. 13) In the present study, we investigated the pharmacogenetic variability in the disposition of carvedilol, because CYP2C9, CYP2C19, CYP3A5, UGT2B7, and MDR1 as well as CYP2D6 are genetically polymorphic in the Japanese population. That is, we estimated the pharmacokinetic parameters of R-and S-carvedilol in 54 healthy Japanese volunteers with the Bayesian method using a nonlinear mixed effects model (NONMEM) program. We then examined the effect of polymorphisms of CYP2D6, CYP2C9, CYP2C19, CYP3A5, UGT2B7, and MDR1 on the pharmacokinetic variability of carvedilol using a multiple regression analysis.
METERIALS AND METHODS

Subjects and Study Protocols
Fifty-four healthy Japanese volunteers (38 men and 16 women) participated in the present study. Twenty-three subjects of them also partici- pated in the previous study. 8) The age was between 22 and 44 years old (mean: 26.5), and the body weight was between 41 and 86 kg (mean: 60.9). They were given 5 mg (two 2.5 mgtablets: 9 men and 14 women) or 10 mg (one 10 mg-tablet: 29 men and 2 women) of carvedilol (Artist ® tablet; Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan) with a glass of water at least 2 h before the meal. Because the peak blood carvedilol concentrations are attained at 0.5-1 h after oral administration following an over night fast, 6) we designed the sampling protocol where 5 ml of blood was withdrawn at 2 and 6 h after dosing. Genomic DNA was isolated from the peripheral blood with an extraction kit (Qiagen, Hilden, Germany), and was stored at Ϫ80°C. All the subjects were physicians or pharmacists, and they chose the dose of carvedilol by themselves. The mean (ϮS.D.) body weight in the subjects taking 5 mg and 10 mg of carvedilol was 53.3Ϯ6.8 kg and 66.5Ϯ 8.9 kg, respectively. All subjects gave written consent to participate in this study, which was approved by the ethics committee of Toyama Medical and Pharmaceutical University.
Genotyping of CYP2D6 Among Asian subjects, the three most common alleles of the CYP2D6 gene are CYP2D6*1, *2, and *10. The mutant allele of CYP2D6 (CYP2D6*2) does not affect the enzyme activity, whereas the CYP2D6*10 allele causes the low expression and affinity of CYP2D6. 14, 15) In addition, CYP2D6*5 and *14 were the common defective alleles in Asian subjects.
16) The detection of CYP2D6*2, *10, *5, and *14 was reported previously. 8) Genotyping of CYP2C9 and CYP2C19 CYP2C9*3 is a mutant allele which confers less metabolic activity than CYP2C9*1 for drugs, such as S-warfarin, tolbutamide, and phenytoin.
10) The genetic variants (CYP2C19*2 and *3) lead to a defect in the functional CYP2C19 protein. 17) The alleles, CYP2C9*3, CYP2C19*2, and CYP2C19*3, were determined using the polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method. 18, 19) Genotyping of CYP3A5 and UGT2B7 A variant allele of CYP3A5 (CYP3A5*3) confers low CYP3A5 expression as a result of improper mRNA splicing. 20) Midazolam hydroxylation activity of donors' livers with at least one CYP3A5*1 allele is significantly higher than that of donors' livers with CYP3A5*3/*3. 21) A common polymorphism in the UGT2B7 gene (UGT2B7*2) has been found in Japanese with a frequency of 0.293, although its effect on enzymatic activity is unclear. CYP3A5*3 and UGT2B7*2 were determined by direct sequencing. 22, 23) Genotyping of MDR1 Allelic differences in individual MDR1 gene sequences may be associated with or even causative for different expression levels. 24) Greiner et al. reported that the expression level of the MDR1 gene affects the plasma clearance of digoxin after oral administration. 25) Furthermore, Goto et al. suggests that the MDR1 C3435T polymorphism correlates with the intestinal expression level of CYP3A4.
26) The MDR1 C3435T polymorphism was identified by the PCR-RFLP method. 25) Assay of Carvedilol The blood concentration of carvedilol was measured using chiral high performance liquid chromatography (HPLC) as described by Mihara et al. with minor modifications. 8, 27) Briefly, whole blood samples (0.2 ml) were mixed with 0.5 ml of distilled water to hemolyze the blood cells. After alkalinization with 3 ml of 0.1 mol Britton-Robinson buffer (pH 8), the samples were extracted with 5 ml of diethylether and back-extracted from the organic phase with 0.3 ml of 50 mmol H 2 SO 4 . The organic layer was discarded, and the remaining aqueous phase was alkalinized with 3 ml of 0.1 mol Britton-Robinson buffer (pH 8). This mixture was then re-extracted with 5 ml of diethylether. The organic phase was evaporated dry in a water bath at 45°C. The residue was dissolved in 500 ml of mobile phase, and 50 ml was injected onto the column. The HPLC system consisted of a Shimadzu LC-10AS (Kyoto, Japan). The separation was achieved with a chiral stationary phase column (CHIRALPAC AD-H: 5 mm particle size, 2 mm i.d.ϫ25 cm.; Daicel Chemical Industries, Tokyo, Japan). The temperature of the column oven was set at 40°C. The mobile phase consisted of 75% hexane, 25% isopropanol, and 0.1% (v/v) diethylamine, and the flow rate was 0.3 ml/min. The peaks were monitored at an excitation wavelength of 284 nm and an emission wavelength of 343 nm (Shimadzu RF-10A; Kyoto, Japan). The whole blood carvedilol concentration in each sample was estimated to be the mean value of duplicate measurements. The coefficient of intra-day variation for the assay of R-carvedilol was 2.7% and 4.1% at whole blood concentrations of 0.5 ng/ml and 3 ng/ml, respectively. The coefficient of intra-day variation for the assay of S-carvedilol was 2.3% and 3.0% at whole blood concentrations of 0.5 ng/ml and 3 ng/ml, respectively. The detection limit for each enantiomer was 0.2 ng/ml for its blood concentration.
Estimation of Pharmacokinetic Parameters of Carvedilol in Individual Subjects
Mean pharmacokinetic parameters and their interindividual variations were estimated using the NONMEM analysis, where we used the first-order estimation method in the present study. 14, 28) The pharmacokinetic parameters in individual subjects were obtained from the population estimates according to Bayes' theorem using the NONMEM post-hoc option. The one-compartment model with very rapid absorption was parameterized in terms of the oral clearance (CL/F) and the apparent volume of distribution (V/F), with NONMEM-PREDPP library subroutines, ADVAN1 and TRANS2. 14, 28) The oral clearance in the ith individual (CL/F i ) was modeled using the following equation:
where q 1 is the predicted population mean of the oral clearance, and q 3 is the S/R ratio for CL/F. The S value is fixed to one for S-carvedilol, and to zero for R-carvedilol. WT i is the individual body weight, and h CL/Fi is a random variable distributed with a mean of zero and variance of w 2 CL/F . The apparent volume of distribution in the ith individual (V/F i ) was modeled using the following equation:
where q 2 is the predicted population mean of the apparent volume of distribution, q 4 is the S/R ratio for V/F, and h V/Fi is a random variable distributed with a mean of zero and variance of w 2 V/F . In the present study, we assumed that h CL/Fi is correlated with h V/Fi , and that the covariance is w CL/F,V/F . Finally, the jth observed blood concentration in the ith subject (Cb ij ) was assumed to be randomly and normally distributed from the predicted value (Cb* ij ):
where e ij is a random variable that describes intraindividual variability with a mean of zero and variance of s 2 . Statistical Analysis Values are expressed as the meanϮS.D. The pharmacogenetic variability of carvedilol disposition was investigated by the multiple regression analysis, where the statistical significance of the regression model was evaluated with the likelihood ratio test using the minimum value of the objective function (Ϫ2 log likelihood) produced by NONMEM. 28) RESULTS Table 1 shows the genotypes P450s, UGT2B7, and MDR1 in 54 healthy Japanese volunteers. No subject had the null alleles of CYP2D6 (CYP2D6*5 and *14). Twelve subjects were homozygous for the CYP2D6*1 allele, two were heterozygous for the CYP2D6*1/*2 alleles, and two were homozygous for the CYP2D6*2 allele (Group 1 (G1)). Twenty subjects were heterozygous for the CYP2D6*1/*10 alleles, and six were heterozygous for the CYP2D6*2/*10 alleles (Group 2 (G2)). Twelve subjects were homozygous for the CYP2D6*10 allele (Group 3 (G3)). Forty-eight subjects were homozygous for the CYP2C9*1 allele (G1), and six were heterozygous for the CYP2C9*1/*3 alleles (G2). Twentythree subjects were homozygous for the CYP2C19*1 allele (G1). Eighteen subjects were heterozygous for the CYP2C19*1/*2 alleles and four were heterozygous for the CYP2C19*1/*3 alleles (G2). Four subjects were homozygous for the CYP2C19*2 allele, and five were heterozygous for the CYP2C19*2/*3 alleles (G3). Twenty-five subjects were heterozygous for the CYP3A5*1/*3 alleles (G1), and 29 subjects were homozygous for the CYP3A5*3 allele (G2). Twenty-six subjects were homozygous for the UGT2B7*1 allele (G1), 22 were heterozygous for the UGT2B7*1/*2 alleles (G2), and six were homozygous for the UGT2B7*2 allele (G3). For the MDR1 C3435T polymorphism, 25 subjects had the CC genotype (G1), 25 subjects had the CT genotype (G2), and four subjects had the TT genotype (G3).
The whole blood concentrations of R-and S-carvedilol enantiomers in 54 healthy volunteers are shown in Figs. 1  and 2 . The blood concentration of R-carvedilol was higher than that of S-carvedilol in all 54 subjects. The blood concentration of both enantiomers seemed to be higher in the G2 CYP2D6 and G3 CYP2D6 subjects than in the G1 CYP2D6 subjects. Table 2 shows the population pharmacokinetic parameters of carvedilol estimated with NONMEM. The q 1 and q 2 values of R-carvedilol were estimated to be 1.88 l/h/kg and 4.92 l/kg, respectively. The q 3 and q 4 values that indicate the S/R ratio for CL/F and V/F were estimated to be 2.47 and 2.92, respectively. NONMEM provides estimates of the standard error (S.E.) for all parameters, and S.E. can be used to define 95% confidence intervals (CI) for true parameter values: 95% CIϭ(the estimated parameter value)Ϯ1.96 · S.E. The obtained 95% CI values for q 3 and q 4 indicated that the CL/F and V/F values for S-carvedilol were significantly greater than those for R-carvedilol ( Table 2 ). The w 2 CL/F value was estimated to be 0.176, which indicated that the coefficient of variation of CL/F was 42.0%. Similarly, the estimated w Table 4 summarizes the multiple regression analysis models for V/F. The LLD value between Model 1 and Model 2 was 19.15 for R-carvedilol and 8.65 for S-carvedilol, which indicated that the V/F values were correlated with the number of the CYP2D6*10 alleles (pϽ0.01). Models 3-12 were designed to investigate the effects of genotypes of CYP2C9, CYP2C19, CYP3A5, UGT2B7, and MDR1 on V/F. The LLD value between Model 1 and Model 3 was 4.70 for Rcarvedilol, which suggested that the effect of the CYP2C9 polymorphism on V/F was only slight (pϽ0.05). The LLD value between Model 2 and Model 10 was 3.79 for Rcarvedilol, which indicated that the effect of the CYP3A5 polymorphism on V/F was not significant. Figure 5A shows the effect of the CYP2D6 and CYP3A5, genotypes on the individual (V/F)/WT values of R-carvedilol. The mean (V/F)/WT value of R-carvedilol in the G1 CYP2D6 , G2 CYP2D6 , and G3 CYP2D6 subjects was 7.2Ϯ2.4, 5.2Ϯ2.0, and 4.2Ϯ 1.4 l/kg, respectively. On the other hand, Fig. 5B shows the effect of the CYP2D6 and UGT2B7 genotypes on the individual (V/F)/WT values of S-carvedilol. The mean (V/F)/WT value of S-carvedilol in the G1 CYP2D6 , G2 CYP2D6 , and G3 CYP2D6 subjects was 18.6Ϯ5.8, 14.6Ϯ5.2, and 13.4Ϯ4.6 l/kg, respectively. The V/F values of S-carvedilol in G2 UGT2B7 and G3 UGT2B7 were similar to those in G1 UGT2B7 . Therefore, we chose Model 2 as the final model to describe the V/F of R-and S-carvedilol in healthy Japanese.
The mean values of V/F were estimated to be the follow- Table 4 . Analysis Models for the V/F of Carvedilol 
DISCUSSION
In the present study, we evaluated the pharmacogenetic variability in the disposition of carvedilol in 54 Japanese populations using a multiple regression analysis. Our study had two major findings. First, (CL/F)/WT and (V/F)/WT values of R-and S-carvedilol were significantly lower in the G2 CYP2D6 and G3 CYP2D6 subjects than G1 CYP2D6 subjects, confirming our previous finding that the systemic and/or pre-systemic metabolism of the drug in the liver is significantly decreased in Japanese with the CYP2D6*10 allele.
8) Second, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A5*3, UGT2B7*2, and MDR1 C3435T did not significantly affect the pharmacokinetics of carvedilol in Japanese subjects.
Many drugs undergo substantial metabolism in the intestine as well as the liver, after their absorption from the gut lumen. 29) CYP3A4 and P-glycoprotein (P-gp) are jointly expressed in the intestine, and it is believed that the low oral bioavailability of some drugs results largely from the actions of these two enzymes. 30) At present, it is unclear whether orally administered carvedilol is significantly metabolized in the intestinal tissue. On the other hand, Giessmann et al. reported that 36.8% of the dose (unchanged carvedilol, 13.4%; its oxidative metabolites, 23.4%) was excreted into the feces following the intravenous administration of 5 mg of carvedilol to healthy subjects, and that the cumulative fecal excretion of carvedilol after the intravenous administration is highly correlated with the mRNA expression of P-gp in the intestine.
13) Therefore, we had thought that the CL/F and V/F values of carvedilol could be altered by the interindividual variability of the intestinal expression of P-gp. However, MDR1 C3435T did not significantly affect the pharmacokinetics of carvedilol in Japanese subjects (Tables 3, 4) , which suggested that the MDR1 C3435T polymorphism may not always be correlated with the mRNA and/or protein expression of P-gp. Hoffmeyer et al. reported that the homozygote with mutant T allele had a significantly lower duodenal MDR1 expression than the homozygote with the wild-type allele (C/C). 24) In contrast, Nakamura et al. demonstrated that the T/T genotype of MDR1 C3435T was associated with a higher level of MDR1 mRNA in the duodenum in Japanese subjects. 31) In addition, Goto et al. reported that the identified polymorphisms including C3435T in the MDR1 gene had no influence on the intestinal expression of MDR1 mRNA. 26) Zhou et al. reported that the mean CL/F value of Rcarvedilol is 67% lower in poor metabolizers than in extensive metabolizers of CYP2D6, and that the mean CL/F value of S-carvedilol in the poor metabolizers is 24% lower than that in the extensive metabolizers, suggesting that CYP2D6 is more responsible for the metabolism of R-carvedilol. 32) The present findings are in line with those reported by Zhou et al. That is, the mean (CL/F)/WT value of R-carvedilol in the subjects with CYP2D6*10/*10 was 51.3% lower than that in the subjects without the CYP2D6*10 allele. On the other hand, the mean (CL/F)/WT value of S-carvedilol in the subjects with CYP2D6*10/*10 was only 30.8% lower than that in the subjects with CYP2D6*1/*1, *1/*2, or *2/*2 (Fig.  4) . In addition, we also found the significant effect of CYP2D6*10 on the (V/F)/WT values of R-and S-carvedilol in the present study. That is, the (V/F)/WT values were lower in the subjects with CYP2D6*1/*10, *2/*10 or *10/*10 than in the subjects with CYP2D6*1/*1, *1/*2, or *2/*2 (Fig. 5) . The result indicated that bioavailability (F) of carvedilol was increased in the patients with CYP2D6*10, because it was unlikely that the genetic mutation of CYP2D6 would affect the distribution volume (V) of the drug. In addition, the reduced hepatic first-pass extraction of carvedilol may be responsible for the increased bioavailability (F) in the subjects with CYP2D6*10, because it is unlikely that CYP2D6*10 would affect the intestinal absorption of the drug. The increased bioavailability (F) of carvedilol, therefore, can theoretically lead to the reduced hepatic extraction and also the decreased systemic clearance (CL) in the patients with CYP2D6*10.
Metoprolol is a b 1 -selective adrenoceptor blocker and has also been used to treat cardiovascular diseases. The b 1 -antagonistic activity of the drug resides mainly in the S-enantiomer, but the pharmacokinetics of S-metoprolol is similar to that of R-metoprolol. 33) In the previous study, therefore, we measured the total (R-plus S-enantiomer) blood concentration of metoprolol in routinely treated Japanese patients, and evaluated the effect of CYP2D6*10 on the oral clearance of the drug.
14) The mean CL/F value of metoprolol in the patients with CYP2D6*10/*10 was 64% lower than that in the patients with CYP2D6*1/*1 or *1/*2. 14) In addition, isoproterenol-induced percentage increases in heart rate in Japanese patients with CYP2D6*10/*10, who were routinely treated with metoprolol, were less than those in the patients with CYP2D6*1/*1 or *1/*2. 34) These findings suggested that a lower dose of metoprolol may be used in the patients with CYP2D6*10. 14, 34) In conjunction with the previous study, the present findings suggested that the pharmacokinetic variability of S-carvedilol is smaller than that of metoprolol (Fig. 4) . The b 1 -and b 2 -blockades of carvedilol are principally attributable to the S-enantiomer; however, Renantiomer as well as S-enantiomer exhibits a 1 -blockade and potent antioxidant properties.
35) The a 1 -blockade of carvedilol causes arterial vasodilation, whereas the antioxidant effect of the drug may be clinically important, because oxygen free radicals can cause myocyte apoptosis, myocardial b-adorenergic receptor signal transduction abnormalities, and contractile dysfunction. 35) Further studies are needed to clarify whether the optimal dose of carvedilol in Japanese patients with the CYP2D6*10 allele is different from that in Japanese and/or Caucasian extensive metabolizers.
In conclusion, though poor metabolism through CYP2D6 is found in only less than 1% of Asians, the oral clearance of carvedilol is significantly decreased in Japanese subjects with a common allele, CYP2D6*10. On the other hand, CYP2C9*3, CYP2C19*2, CYP2C19*3, CYP3A5*3, UGT2B7*2, and MDR1 C3435T did not significantly affect the pharmacokinetics of carvedilol. These findings provide new insight into the interindividual variability and interethnic difference in the pharmacokinetics of carvedilol.
